Auspex Pharmaceuticals Inc (ASPX): Deerfield Management Increase its Stake Following the Latest Public Offering of Stock

Auspex Pharmaceuticals is a $1.65 billion market cap biopharmaceutical company, which specializes in the development and commercialization of unprecedented medicines designed for the treatment of orphan diseases. A few weeks ago, one of the firm’s latest developments – a compound used in the treatment of children with Tourette syndrome – was approved by the U.S. Food and Drug Administration (FDA). In addition to this positive announcement, the company revealed it has been developing a new drug, which could potentially find widespread use in the treatment of Parkinson’s disease and other movement related disorders. Thanks to its latest stock offering, Auspex has acquired the necessary funds to expand its research and development even further.

According to the quarterly results presented in November, Auspex Pharmaceuticals (NASDAQ:ASPX)’s stock delivered losses amounting to $0.73 per share, thus missing the consensus estimate of by $0.45 per share. For the next quarter, analysts’ average consensus estimate sets losses at $0.55 per share. Furthermore, the company is projected to report losses of $2.52 per share during the fourth quarter of 2015, according to the consensus estimate. Nevertheless, the stock is projected to grow around 28% during this quarter and could exceed expectations if their latest developments achieve the desired results. Overall, Deerfield Management seems to consider Auspex as a long-term investment, displaying a very bullish stance towards the company.